Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
Helius Medical Technologies (NASDAQ:HSDT) has announced the establishment of Revelation Neuro, a wholly-owned private subsidiary focused on developing non-implantable AI-powered Brain Computer Interface (BCI) technology. The subsidiary will leverage Helius' existing IP portfolio and extensive data warehouse for AI algorithm development.
The new venture aims to create a personalized neurorehabilitation solution using translingual stimulation without implantation. Revelation Neuro will utilize Helius' dataset of over 5 years of movement dysfunction clinical evidence from 400+ subjects as the foundation for AI algorithm development. The technology focuses initially on motor function rehabilitation, with potential future applications in cognitive deficit, mood, and behavior disorders.
While Helius will assign its newly developed IP and license existing IP to Revelation Neuro, the company does not plan to invest significant additional capital. Instead, the subsidiary is expected to be financed through third-party outside sources, building upon the $70 million already invested in neuromodulation technology development.
Helius Medical Technologies (NASDAQ:HSDT) ha annunciato l'istituzione di Revelation Neuro, una sussidiaria privata interamente controllata, focalizzata sullo sviluppo di tecnologia per interfacce cervello-computer (BCI) alimentate da intelligenza artificiale e non impiantabili. La sussidiaria sfrutterà il portafoglio di proprietà intellettuale esistente di Helius e il vasto magazzino di dati per lo sviluppo di algoritmi AI.
La nuova iniziativa mira a creare una soluzione personalizzata di neuro-riabilitazione utilizzando la stimolazione translinguale senza impianto. Revelation Neuro utilizzerà il dataset di Helius, che comprende oltre 5 anni di evidenze cliniche sui disturbi del movimento di oltre 400 soggetti, come base per lo sviluppo degli algoritmi AI. La tecnologia si concentrerà inizialmente sulla riabilitazione della funzione motoria, con potenziali applicazioni future in deficit cognitivi, disturbi dell'umore e comportamentali.
Pur assegnando la sua nuova proprietà intellettuale e concedendo in licenza la proprietà esistente a Revelation Neuro, Helius non prevede di investire capitale aggiuntivo significativo. Al contrario, si prevede che la sussidiaria sia finanziata attraverso fonti esterne di terzi, costruendo sui 70 milioni di dollari già investiti nello sviluppo della tecnologia di neuromodulazione.
Helius Medical Technologies (NASDAQ:HSDT) ha anunciado el establecimiento de Revelation Neuro, una subsidiaria privada de propiedad total centrada en el desarrollo de tecnología de interfaz cerebro-computadora (BCI) impulsada por inteligencia artificial y no implantable. La subsidiaria aprovechará el portafolio de propiedad intelectual existente de Helius y su amplio almacén de datos para el desarrollo de algoritmos de IA.
La nueva empresa tiene como objetivo crear una solución de neurorehabilitación personalizada utilizando estimulación translingual sin implantación. Revelation Neuro utilizará el conjunto de datos de Helius, que incluye más de 5 años de evidencia clínica sobre disfunciones del movimiento de más de 400 sujetos, como base para el desarrollo de algoritmos de IA. La tecnología se centrará inicialmente en la rehabilitación de la función motora, con posibles aplicaciones futuras en déficit cognitivo, trastornos del estado de ánimo y del comportamiento.
Aunque Helius asignará su nueva propiedad intelectual y licenciará la propiedad existente a Revelation Neuro, la empresa no planea invertir capital adicional significativo. En su lugar, se espera que la subsidiaria sea financiada a través de fuentes externas de terceros, construyendo sobre los 70 millones de dólares ya invertidos en el desarrollo de tecnología de neuromodulación.
Helius Medical Technologies (NASDAQ:HSDT)는 Revelation Neuro라는 완전 소유의 민간 자회사를 설립했다고 발표했습니다. 이 자회사는 비임플란트형 인공지능(AI) 기반 뇌-컴퓨터 인터페이스(BCI) 기술 개발에 주력합니다. 이 자회사는 Helius의 기존 지식 재산 포트폴리오와 AI 알고리즘 개발을 위한 방대한 데이터 웨어하우스를 활용할 것입니다.
새로운 사업은 임플란트 없이 다국어 자극을 사용하여 개인 맞춤형 신경 재활 솔루션을 만드는 것을 목표로 합니다. Revelation Neuro는 400명 이상의 피험자에서 5년 이상의 운동 기능 장애에 대한 임상 증거로부터 Helius의 데이터 세트를 AI 알고리즘 개발의 기초로 활용할 것입니다. 이 기술은 초기에는 운동 기능 재활에 중점을 두며, 향후에는 인지 결핍, 기분 및 행동 장애에 대한 응용 가능성이 있습니다.
Helius는 새로 개발된 지식 재산을 Revelation Neuro에 할당하고 기존 지식 재산에 대한 라이센스를 부여할 예정이지만, 추가 자본을 대규모로 투자할 계획은 없습니다. 대신, 이 자회사는 제3자의 외부 자원을 통해 자금을 조달할 것으로 예상되며, 이미 신경 조절 기술 개발에 투자된 7000만 달러를 기반으로 할 것입니다.
Helius Medical Technologies (NASDAQ:HSDT) a annoncé la création de Revelation Neuro, une filiale privée entièrement détenue, axée sur le développement d'une technologie d'interface cerveau-ordinateur (BCI) alimentée par l'IA et non implantable. La filiale tirera parti du portefeuille de propriété intellectuelle existant de Helius et de son vaste entrepôt de données pour le développement d'algorithmes d'IA.
La nouvelle entreprise vise à créer une solution de neuroréhabilitation personnalisée utilisant une stimulation translinguale sans implantation. Revelation Neuro utilisera l'ensemble de données de Helius, qui comprend plus de 5 ans de preuves cliniques sur les dysfonctionnements du mouvement provenant de plus de 400 sujets, comme base pour le développement des algorithmes d'IA. La technologie se concentrera initialement sur la réhabilitation des fonctions motrices, avec des applications futures potentielles dans les déficits cognitifs, les troubles de l'humeur et du comportement.
Bien qu'Helius attribue sa nouvelle propriété intellectuelle et accorde des licences pour la propriété existante à Revelation Neuro, l'entreprise ne prévoit pas d'investir un capital supplémentaire significatif. Au lieu de cela, il est prévu que la filiale soit financée par des sources externes tierces, s'appuyant sur les 70 millions de dollars déjà investis dans le développement de la technologie de neuromodulation.
Helius Medical Technologies (NASDAQ:HSDT) hat die Gründung von Revelation Neuro bekannt gegeben, einer vollständig im Besitz befindlichen privaten Tochtergesellschaft, die sich auf die Entwicklung von nicht implantierbarer, KI-gestützter Gehirn-Computer-Schnittstellentechnologie (BCI) konzentriert. Die Tochtergesellschaft wird das bestehende IP-Portfolio von Helius sowie das umfangreiche Datenlager für die Entwicklung von KI-Algorithmen nutzen.
Das neue Unternehmen hat zum Ziel, eine personalisierte neurorehabilitative Lösung unter Verwendung von translingualer Stimulation ohne Implantation zu schaffen. Revelation Neuro wird den Datensatz von Helius mit über 5 Jahren klinischer Evidenz zu Bewegungsstörungen von über 400 Probanden als Grundlage für die Entwicklung von KI-Algorithmen nutzen. Die Technologie konzentriert sich zunächst auf die Rehabilitation der motorischen Funktionen, mit möglichen zukünftigen Anwendungen in kognitiven Defiziten, Stimmungs- und Verhaltensstörungen.
Obwohl Helius sein neu entwickeltes IP an Revelation Neuro zuweist und bestehende IP lizenziert, plant das Unternehmen nicht, signifikant zusätzliches Kapital zu investieren. Stattdessen wird erwartet, dass die Tochtergesellschaft durch externe Drittquellen finanziert wird, basierend auf den bereits investierten 70 Millionen Dollar in die Entwicklung von Neuromodulationstechnologie.
- Creation of new subsidiary to expand into AI-powered BCI technology market
- Leveraging existing $70M investment and extensive clinical data
- No significant additional capital required from HSDT
- Potential expansion into multiple neurological treatment areas
- Dependence on third-party financing for subsidiary development
- No immediate revenue generation potential mentioned
- Unproven AI technology effectiveness
Insights
Helius Medical Technologies' formation of Revelation Neuro represents a calculated strategic expansion into the rapidly developing Brain Computer Interface (BCI) space. Unlike many competitors pursuing invasive implants, Helius is leveraging its existing non-invasive translingual stimulation technology—already demonstrated in clinical settings—and combining it with AI algorithms to create a potentially differentiated BCI approach.
What's financially significant is Helius's capital-efficient approach. The company intends to transfer IP to Revelation Neuro while specifically noting they "do not intend to invest significant additional capital" but instead expect third-party financing. This structure potentially allows Helius to maintain 100% ownership while minimizing additional capital requirements—essentially creating an optionality vehicle for future growth without immediate dilution to existing shareholders.
The subsidiary formation leverages Helius's substantial prior investments (over
While the BCI field is competitive and regulatory pathways remain complex, this subsidiary structure provides Helius a segmented approach to pursue higher-risk/reward technology development while maintaining its core business focus on balance and gait therapies.
--Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence (“AI”) Powered BCI Technology--
--Helius’ existing IP portfolio and extensive data warehouse provides a solid foundation for AI algorithm development--
--Helius to Present at the 37th Annual ROTH Conference on Monday, March 17 at 12:00pm PT--
NEWTOWN, Pa., March 13, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for improving balance and gait deficits and reducing the risk of falling, today announced the establishment of Revelation Neuro, Inc. (“Revelation Neuro”), its wholly-owned private subsidiary focused on the development of non-implantable AI powered BCI technology.
“We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of care for personalized neurorehabilitation using a non-implantable AI powered BCI combining our newly developed intellectual property (“IP”) with Helius’ existing IP. Our technology relies on its proven ability to modulate known target brain processes and trigger therapeutic responses by using translingual stimulation without risky implantation. We believe Revelation Neuro’s BCI technology will be a unique and less invasive therapeutic option,” said Dane Andreeff, Helius President and Chief Executive Officer.
“Revelation Neuro is focused on maximizing the positive effect of neuromodulation by applying AI to optimize individual response to translingual stimulation,” Andreeff continued. “Helius’ extensive dataset, comprised of more than 5 years of movement dysfunction clinical evidence from over 400 subjects, will serve as the initial foundation for AI algorithm development to which new patient data will then be added to optimize the algorithm and enable a precise and personalized approach to motor function rehabilitation. Revolutionary BCI-enabled improvement in functional rehabilitation is the initial focus of Revelation Neuro’s efforts, with the potential in the future to address neurological conditions including cognitive deficit, mood and behavior disorders.”
Revelation Neuro is a private subsidiary
Roth Conference Participation
The Company plans to present at the upcoming 37th Annual Roth Conference in Dana Point, California. Helius management, Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, is scheduled to present on Monday, March 17, 2025 at 12:00pm PT. A live and recorded webcast of the presentation will be available on the “Events” page of the Company’s investor website at ir.heliusmedical.com.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information about PoNS or Helius Medical Technologies, visit www.heliusmedical.com.
Cautionary Disclaimer Statement
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements that BCI technology will be a unique and less invasive therapeutic option, that it will lead to improvements in rehabilitation of motor and cognitive functions, statements related to the ability to expedite development, and statements related to Helius’s intended capitalization of Revelation Neuro.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, market conditions and availability of funds from third parties to finance Revelation Neuro, Inc., the Company’s ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company’s ability to obtain adequate Medicare insurance coverage and to obtain a reimbursement code, the Company’s ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Investor Relations Contact
Philip Trip Taylor
Gilmartin Group
investorrelations@heliusmedical.com
FAQ
What is the purpose of Helius Medical's new subsidiary Revelation Neuro?
How much clinical data does HSDT have for AI algorithm development?
How will HSDT finance Revelation Neuro's operations?
What conditions does Revelation Neuro's BCI technology aim to treat?
